Clinical utility of serum biomarkers for hepatocellular carcinoma

References

• 1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 391(10127), 1301–1314 (2018).
  MedlineGoogle Scholar
• 2. Tanaka M, Katayama F, Kato H et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J. Epidemiol. 21(6), 401–416 (2011).
  MedlineGoogle Scholar
• 3. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J. Hepatol. 72(2), 250–261 (2020).
  Medline CASGoogle Scholar
• 4. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908–943 (2012).
  MedlineGoogle Scholar
• 5. Marrero JA, Kulik LM, Sirlin CB et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68(2), 723–750 (2018).
  MedlineGoogle Scholar
• 6. Johnson PJ, Pirrie SJ, Cox TF et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol. Biomarkers Prev. 23(1), 144–153 (2014).
  Medline CASGoogle Scholar
• 7. Yang T, Xing H, Wang G et al. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clin. Chem. 65(12), 1543–1553 (2019).
  Medline CASGoogle Scholar
• 8. Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 15(11), 1301–1314 (2009).
  MedlineGoogle Scholar
• 9. Trevisani F, D'Intino PE, Morselli-Labate AM et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol. 34(4), 570–575 (2001).
  Medline CASGoogle Scholar
• 10. Zhu AX, Kang YK, Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 20(2), 282–296 (2019).
  Medline CASGoogle Scholar
• 11. Personeni N, Bozzarelli S, Pressiani T et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J. Hepatol. 57(1), 101–107 (2012).
  Medline CASGoogle Scholar
• 12. Xu XF, Xing H, Han J et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 154(3), 209–217 (2019).
  MedlineGoogle Scholar
• 13. Zhu R, Yang J, Xu L et al. Diagnostic performance of des-γ-carboxy prothrombin for hepatocellular carcinoma: a meta-analysis. Gastroenterol. Res. Pract. 2014, 529314 (2014).
  MedlineGoogle Scholar
• 14. Nomura F, Ishijima M, Horikoshi A, Nakai T, Ohnishi K. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. Am. J. Gastroenterol. 91(7), 1380–1383 (1996).
  Medline CASGoogle Scholar
• 15. Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 18(4), 990–997 (1993).
  Medline CASGoogle Scholar
• 16. Okuda H, Nakanishi T, Takatsu K et al. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 85(4), 812–818 (1999).
  Medline CASGoogle Scholar
• 17. Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 21(37), 10573–10583 (2015).
  Medline CASGoogle Scholar
• 18. Saeki I, Yamasaki T, Tanabe N et al. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy. PLoS ONE 10(5), e0126649 (2015).
  MedlineGoogle Scholar
• 19. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin. Chim. Acta 313(1-2), 15–19 (2001).
  Medline CASGoogle Scholar
• 20. Sterling RK, Jeffers L, Gordon F et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am. J. Gastroenterol. 102(10), 2196–2205 (2007).
  MedlineGoogle Scholar
• 21. Marrero JA, Feng Z, Wang Y et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137(1), 110–118 (2009).
  Medline CASGoogle Scholar
• 22. Tada T, Kumada T, Toyoda H et al. Relationship between lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int. 25(4), 848–853 (2005).
  Medline CASGoogle Scholar
• 23. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 111(4), 996–1001 (1996).
  Medline CASGoogle Scholar
• 24. Berhane S, Toyoda H, Tada T et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin. Gastroenterol. Hepatol. 14(6), 875–886.e6 (2016).
  Medline CASGoogle Scholar
• 25. Yang JD, Addissie BD, Mara KC et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol. Biomarkers Prev. 28(3), 531–538 (2019).
  MedlineGoogle Scholar
• 26. Toyoda H, Kumada T, Osaki Y et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin. Gastroenterol. Hepatol. 4(12), 1528–1536 (2006).
  Medline CASGoogle Scholar
• 27. Fox R, Berhane S, Teng M et al. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. Br. J. Cancer 110(8), 2090–2098 (2014).
  Medline CASGoogle Scholar
• 28. Golubnitschaja O, Polivka J Jr, Yeghiazaryan K, Berliner L. Liquid biopsy and multiparametric analysis in management of liver malignancies: new concepts of the patient stratification and prognostic approach. EPMA J. 9(3), 271–285 (2018).
  MedlineGoogle Scholar
• 29. Lu M, Zhan X. The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA J. 9(1), 77–102 (2018).
  MedlineGoogle Scholar
• 30. Goldstein E, Yeghiazaryan K, Ahmad A, Giordano FA, Fröhlich H, Golubnitschaja O. Optimal multiparametric set-up modelled for best survival outcomes in palliative treatment of liver malignancies: unsupervised machine learning and 3 PM recommendations. EPMA J. 11(3), 505–515 (2020).
  MedlineGoogle Scholar